Rabies is a viral infection of the central nervous system for which vaccination is the only treatment possible. Besides preexposure, vaccination is highly recommended for people living in endemic areas, veterinarians, and laboratory workers. Our group has developed rabies virus-like particles (RV-VLPs) with immunogenic features expressed in mammalian cells for vaccine applications. In this chapter the methods to obtain and characterize a stable HEK293 cell line expressing RV-VLPs are detailed. Further, analytical ultracentrifugation steps to purify the obtained VLPs are developed, as well as western blot, dynamic light scattering, and immunogold electron microscopy to analyze the size, distribution, shape, and antigenic conformation of the purified particles. Finally, immunization protocols are described to study the immunogenicity of RV-VLPs.
Vaccine development Virus-like particles Rabies Lentiviral vectors Stable cell line HEK293
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
The authors would like to thank Juan Pablo Soto (Institutional Image, Universidad Nacional del Litoral, Argentina) for technical support.
Fontana D, Kratje R, Etcheverrigaray M, Prieto C (2014) Rabies virus-like particles expressed in HEK293 cells. Vaccine 32:2799–2804CrossRefPubMedGoogle Scholar
Wu CY, YehYC YYC, Chou C, Liu MT, Wu HS, Chan JT, Hsiao PW (2010) Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. Plos One 5(3):e784CrossRefGoogle Scholar
Chuan Li C, Liu F, Liang M, Zhang Q, Wang X, Wang T, Li J, Li D (2010) Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice. Vaccine 28:4294–4300CrossRefPubMedGoogle Scholar
Hua RH, Li YN, Chen ZS, Liu LK et al (2014) Generation and characterization of a new mammalian cell line continuously expressing virus-like particles of Japanese encephalitis virus for a subunit vaccine candidate. BMC Biotechnol 14:62CrossRefPubMedPubMedCentralGoogle Scholar
Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463–8471PubMedPubMedCentralGoogle Scholar
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263–267CrossRefPubMedGoogle Scholar
Picanço-Castro V, Fontes AM, de Sousa Russo-Carbolante EM, Covas DR (2008) Lentiviral-mediated gene transfer – a patent review. Expert Opin Ther Pat 18(5):1–15CrossRefGoogle Scholar
Zeltins A (2012) Construction and characterization of virus-like particles: a review. Mol Biotechnol 53:92–107CrossRefGoogle Scholar
Wilbur LA, Aubert MFA (1996) The NIH potency test. In: Meslin FX, Kaplan MM, Koprowsky H (eds) Laboratory techniques in rabies. WHO, Geneva, Switzerland, pp 360–366Google Scholar
Prieto C, Fontana D, Etcheverrigaray M, Kratje R (2011) A strategy to obtain recombinant cell lines with high expression levels. Lentiviral vector-mediated transgenesis. BMC Proc 5(8):P7CrossRefPubMedPubMedCentralGoogle Scholar